Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Delamanid + Bedaquiline + Optimized Background Regimen (OBR)
Treatment for HIV/AIDS - Extensively drug-resistant Tuberculosis
Typical Dosage: Delamanid: 100mg twice daily (6 months); Bedaquiline: 400mg daily (2 weeks), then 200mg 3x/week (22 weeks); OBR drugs (e.g., Clofazimine 100mg daily, Cycloserine 250-500mg twice daily)
Effectiveness
75%
Safety Score
32%
Clinical Trials
15
Participants
1.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
32
DangerousModerateSafe
Treatment Details
Dosage Range
Delamanid: 100mg twice daily (6 months); Bedaquiline: 400mg daily (2 weeks), then 200mg 3x/week (22 weeks); OBR drugs (e.g., Clofazimine 100mg daily, Cycloserine 250-500mg twice daily)
Time to Effect
2-3 months (sputum conversion), 3-6 months (clinical improvement)
Treatment Duration
18-24 months
Evidence Quality
MODERATENumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
8(Treat 8 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$53,000
Monitoring:$7,000
Side Effect Mgmt:$8,000
Total Annual:$68,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$11,333/QALY
QALYs Gained
6
Outcome-Based Costs
Cost per Responder
$90,667
Cost per Remission
$90,667
Comparison vs Individualized regimen without novel drugs or with injectables
Cost Difference
+$10,000/year
More expensive
QALY Difference
+1.50 QALYs
Better outcomes
Dominance
No dominance
Delamanid + Bedaquiline + Optimized Background Regimen (OBR) Outcomes
for HIV/AIDS - Extensively drug-resistant Tuberculosis
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+75%
Remission Rate
+75%
Common Side Effects
QT prolongation
+20%
Hepatotoxicity
+15%
Skin discoloration (from Clofazimine in OBR)
+90%
Gastrointestinal issues
+30%
Neuropsychiatric effects (from Cycloserine in OBR)
+25%
Peripheral neuropathy
+10%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov